Bictegravir/emtricitabine/tenofovir alafenamide in older individuals with HIV: Results of a 96-week, phase 3b, open-label, switch trial in virologically suppressed people ≥65 years of age

  1. Maggiolo, F.
  2. Rizzardini, G.
  3. Molina, J.-M.
  4. Pulido, F.
  5. De Wit, S.
  6. Vandekerckhove, L.
  7. Berenguer, J.
  8. D'Antoni, M.L.
  9. Blair, C.
  10. Chuck, S.K.
  11. Piontkowsky, D.
  12. Martin, H.
  13. Haubrich, R.
  14. McNicholl, I.R.
  15. Gallant, J.
Journal:
HIV Medicine

ISSN: 1468-1293 1464-2662

Year of publication: 2023

Volume: 24

Issue: 1

Pages: 27-36

Type: Article

DOI: 10.1111/HIV.13319 GOOGLE SCHOLAR lock_openOpen access editor

Sustainable development goals